Management of supraesophageal complications of gastroesophageal reflux disease in infants and children.
Therapy of supraesophageal manifestations of gastroesophageal reflux disease (GERD) in infants and children nearly always includes "lifestyle modifications" (conservative or nonpharmacologic therapy). Depending on the severity of the GERD manifestation, pharmacotherapy is often added. Although data to support the practice are not abundant, it is rational to begin with prokinetic pharmacotherapy and to add acid suppression if pathologic effects of acid contact with the esophagus or airway are suspected. Pathologic effects of acid produce most forms of supraesophageal GERD; the exception is infantile regurgitation, the most common example of supraesophageal GERD, which is often unaccompanied by either esophagitis or evidence of acid entry into the airway. Currently, fundoplication is rarely required for pediatric GERD, but the supraesophageal complications of GERD are more common indications for this surgery than the esophageal complications in children. Other management options for supraesophageal symptoms in children include delivery of nutrients by tube feeding slowly and continuously into the stomach or, better, small intestine. Short-term or trial tube feeding uses a transnasal tube, for example, for nasojejunal feeding; longer-term tube feeding is simplified by a gastrostomy, which can be placed relatively noninvasively using endoscopy or fluoroscopy.
Orenstein
S R
SR
Division of Pediatric Gastroenterology, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Pennsylvania 15213-2583, USA.
D018723:Bethanechol / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002927:Cimetidine / Q000627:therapeutic use; D020117:Cisapride / Q000627:therapeutic use; D018662:Fundoplication; D005764:Gastroesophageal Reflux / Q000150:complications* / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007818:Laryngeal Diseases / Q000209:etiology / Q000517:prevention & control*; D008019:Life Style; D008787:Metoclopramide / Q000627:therapeutic use; D010277:Parasympathomimetics / Q000627:therapeutic use
D005765:Gastrointestinal Agents; D006635:Histamine H2 Antagonists; D010277:Parasympathomimetics; D018723:Bethanechol; D002927:Cimetidine; D008787:Metoclopramide; D020117:Cisapride